This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing
by Zacks Equity Research
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
Insulet's (PODD) New Omnipod, Strategic Moves Drive Growth
by Zacks Equity Research
Insulet (PODD) has been progressing well with respect to its four-pillar strategy, where the first two pillars include expanding access and awareness and delivering consumer-focused innovation.
Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader
by Zacks Equity Research
Abbott (ABT) receives the FDA clearance for a standalone reader to be used for the FreeStyle Libre 3 iCGM system.
Walgreens (WBA) Declares Partnership With Prothena Corporation
by Zacks Equity Research
Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena's Alzheimer's drug candidate, PRX012.
BRKR's Canopy Biosciences Partners With Enable Medicine
by Zacks Equity Research
BRKR's Canopy Biosciences collaborates with Enable Medicine to bring advanced spatial analysis pipelines to the Canopy CellScape System for high-plex spatial biology.
Illumina (ILMN) Partners With Henry Ford Health for NGS Test
by Zacks Equity Research
Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.
Henry Schein (HSIC) Acquires Majority Stake in Biotech Dental
by Zacks Equity Research
Henry Schein (HSIC) announces that the completion of the Biotech Dental partnership brings forth the company's several important solutions to customers.
Quest Diagnostics (DGX) Advances Access to Transplant Services
by Zacks Equity Research
Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.
Select Medical (SEM) Buys Richmond Post-Acute Care Facility
by Zacks Equity Research
Select Medical (SEM) acquires the Vibra Hospital of Richmond to provide enhanced critical illness recovery care across Virginia.
Boston Scientific (BSX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Boston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and the long-term growth prospects of the WATCHMAN device.
Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment
by Zacks Equity Research
Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.
Insulet (PODD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $319.91, moving +0.34% from the previous trading session.
3 Reasons Growth Investors Will Love Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry and the S&P 500 due to impressive quarterly results and segmental prospects.
Insulet (PODD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed at $312.90 in the latest trading session, marking a +0.52% move from the prior day.
Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion
by Zacks Equity Research
Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights Comfort Systems, Hershey, Wynn Resorts, Insulet and Lattice Semiconductor
by Zacks Equity Research
Comfort Systems, Hershey, Wynn Resorts, Insulet and Lattice Semiconductor are included in this Analyst Blog.
Fed Policy Pause & Yellen's Assurance Buoy Wall Street: 5 Picks
by Tirthankar Chakraborty
Thanks to the Fed's willingness to pause its interest rate hikes, it's prudent for investors to place their bets on growth stocks like Comfort Systems USA (FIX), Hershey (HSY), Wynn Resorts (WYNN), Insulet (PODD), and Lattice Semiconductor (LSCC).
Insulet (PODD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Insulet (PODD) closed at $311.49, marking a -1.16% move from the previous day.
Insulet (PODD) Stock Moves -1.05%: What You Should Know
by Zacks Equity Research
In the latest trading session, Insulet (PODD) closed at $309.09, marking a -1.05% move from the previous day.
Insulet (PODD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Insulet (PODD) closed at $312.36, marking a +1.45% move from the previous day.
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) could produce exceptional returns because of its solid growth attributes.
Company News for Mar 14, 2023
by Zacks Equity Research
Companies In The News Are: SGEN, PFE, PODD, SIVB, ILMN, PNC.